Skip to main content

Table 1 Patient baseline characteristics

From: Tranexamic acid and rosuvastatin in patients at risk of cardiovascular events after noncardiac surgery: a pilot of the POISE-3 randomized controlled trial

Characteristic

TXA (N = 49)

TXA placebo (N = 51)

Rosuvastatin (N = 18)

Rosuvastatin placebo (N = 16)

Mean age ± SD, years

70.0 ± 8.2

69.5 ± 8.9

68.4 ± 9.1

68.4 ± 10.6

Male sex, n (%)

26 (53.1)

28 (54.9)

12 (66.7)

6 (37.5)

Eligibility criteria met, n (%)

    

 Age ≥ 45 years

49 (100)

51 (100)

18 (100)

16 (100)

 Preoperative NT-pro-BNP > 100 ng/mL

5 (10.2)

5 (9.8)

1 (5.6)

6 (37.5)

 Patients fulfilling at least one or more of the following 5 criteria

48 (98.0)

50 (98.0)

18 (100)

14 (87.5)

  1. History of coronary disease

15 (30.6)

14 (27.5)

2 (11.1)

1 (6.3)

  2. History of peripheral vascular disease

7 (14.3)

8 (15.7)

5 (27.8)

3 (18.8)

  3. History of stroke

2 (4.1)

1 (2.0)

0 (0.0)

1 (6.3)

  4. Undergoing major vascular surgery

2 (4.1)

3 (5.9)

1 (5.6)

1 (6.3)

  5. Patients fulfilling any 3 of the following risk factors

35 (71.4)

35 (68.6)

13 (72.2)

12 (75.0)

   Undergoing major surgery

29 (59.2)

31 (60.8)

14 (77.8)

12 (75.0)

   History of congestive heart failure

1 (2.0)

3 (5.9)

1 (5.6)

0 (0.0)

   History of transient ischemic attack

2 (4.1)

4 (7.8)

0 (0.0)

0 (0.0)

   Diabetes and currently taking an oral hypoglycemic

19 (38.8)

16 (31.4)

3 (16.7)

4 (25.0)

   Age ≥ 70 years

28 (57.1)

31 (60.8)

11 (61.1)

8 (50.0)

   Hypertension

41 (83.7)

46 (90.2)

15 (83.3)

14 (87.5)

   Serum creatinine > 175 μmol/L

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

   History of smoking within 2 years of surgery

12 (24.5)

14 (27.5)

6 (33.3)

5 (31.3)

   Undergoing emergent/urgent surgery

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

   Mean preoperative hemoglobin ± SD, g/L

134.7 ± 15.7

130.0 ± 14.1

135.3 ± 17.5

137.4 ± 13.3

   Serum creatinine (μmol/L)

88.3 ± 29.2

90.1 ± 27.6

77.7 ± 16.2

80.4 ± 23.9

   Mean time from randomization to start of surgery ± SDa, hours

29.8 ± 18.6

32.2 ± 22.0

29.7 ± 19.9

31.4 ± 21.8

Time from randomization to start of surgery, n (%)

    

  ≤ 24 h

21 (42.9)

24 (47.1)

9 (50.0)

8 (50.0)

 24–48 h

23 (46.9)

18 (35.3)

6 (33.3)

6 (37.5)

  > 48 hb

5 (10.2)

8 (16.0)

3 (16.7)

2 (12.5)

  1. TXA tranexamic acid, SD standard deviation
  2. aPercentages are reported among the total of patients, i.e., the denominator includes also patients in which NT-proBNP was not measured
  3. bAfter excluding from the calculation a patient for whom surgery was canceled after randomization and postponed to 64 days later